<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85616">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01841450</url>
  </required_header>
  <id_info>
    <org_study_id>GTS100-PAS2</org_study_id>
    <nct_id>NCT01841450</nct_id>
  </id_info>
  <brief_title>Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery</brief_title>
  <official_title>A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the long-term safety of the Glaukos® iStent®
      Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery compared to
      cataract surgery only, in subjects with mild to moderate open-angle glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of sight-threatening adverse events</measure>
    <time_frame>60 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other adverse events</measure>
    <time_frame>60 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>For other adverse events such as increase in intra-ocular pressure (IOP) of ≥ 10 mmHg at any time postoperative, loss of best spectacle corrected visual acuity of ≥ 2 lines (≥ 10 letters) postoperative as compared to baseline or best recorded visual acuity measured at any visit postoperative, the rate of each event at each visit will be calculated for the two treatment groups separately.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Diurnal IOP reduction ≥ 20%</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>iStent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of one iStent in conjunction with cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cataract surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract surgery alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent</intervention_name>
    <description>Implantation of one iStent in conjunction with cataract surgery</description>
    <arm_group_label>iStent</arm_group_label>
    <other_name>GTS100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Cataract surgery alone</description>
    <arm_group_label>Cataract surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild to moderate primary open-angle glaucoma

          -  currently treated with ocular hypotensive medication

          -  pseudoexfoliative and pigmentary glaucoma are acceptable diagnoses

          -  subject scheduled to undergo cataract surgery

        Exclusion Criteria:

          -  primary angle-closure glaucoma; or secondary angle closure glaucoma, including
             neovascular glaucoma

          -  retrobulbar tumor, thyroid eye disease, Sturge-Weber syndrome or any other type of
             condition that may cause elevated episcleral venous pressure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silke Thode, PhD</last_name>
    <phone>949-367-9600</phone>
    <email>sthode@glaukos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeff Wells, PharmD, MBA</last_name>
    <phone>949-367-9600</phone>
    <email>jwells@glaukos.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Dedham</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Joseph</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary open-angle glaucoma (POAG)</keyword>
  <keyword>Trabecular meshwork</keyword>
  <keyword>iStent</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
